These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1349028)

  • 21. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy and safety of terazosin.
    Cohen J
    J Clin Pharmacol; 1993 Mar; 33(3):272-8. PubMed ID: 8096524
    [No Abstract]   [Full Text] [Related]  

  • 23. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
    Hayduk K; Schneider HT
    Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
    Lowe FC
    Urology; 1994 Jul; 44(1):46-51. PubMed ID: 7518981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
    Weber MA; Cheung DG; Laddu AR; Luther RR
    Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term experience with terazosin for treatment of mild to moderate hypertension.
    Mersey JH
    Am J Med; 1986 May; 80(5B):68-72. PubMed ID: 2872810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of terazosin and enalapril on laboratory stress testing blood pressure in patients with essential hypertension.
    Cardillo C; Degen C; Campia U; De Felice F; Folli G
    J Clin Pharmacol; 1993 May; 33(5):433-8. PubMed ID: 8101194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension.
    Taylor SH; Lee PS; Sharma SK
    Am Heart J; 1988 Dec; 116(6 Pt 2):1820-5. PubMed ID: 2904757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial.
    Liu H; Liu P; Mao G; Chen G; Wang B; Qin X; Na Y; Liu Z; Wang X; Xu X
    Urology; 2009 Jul; 74(1):130-6. PubMed ID: 19371934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, controlled, multicenter study to compare prazosin GITS with enalapril in hypertensive patients with diabetes mellitus. Bombay Hypertension Study Group.
    Joglekar SJ; Nanivadekar AS
    J Assoc Physicians India; 1998; Suppl 1():52-62. PubMed ID: 11233387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
    Ott P; Storm TL; Krusell LR; Jensen H; Badskjaer J; Faergeman O
    Am J Cardiol; 1987 May; 59(14):73G-77G. PubMed ID: 2884856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of terazosin in the treatment of essential hypertension in blacks.
    Luther RR; Klepper MJ; Maurath CJ; Glassman HN; Achari R; Laddu AR
    J Hum Hypertens; 1990 Apr; 4(2):151-3. PubMed ID: 1971027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of intravenous terazosin in hypertensive patients. A preliminary report.
    Cohen A
    Am J Med; 1986 May; 80(5B):86-93. PubMed ID: 2872814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
    Lytle TB; Coles SJ; Waite MA
    J Clin Pharm Ther; 1991 Aug; 16(4):263-73. PubMed ID: 1682328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experience with doxazosin in general medical practice.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of terazosin as an antihypertensive agent.
    Luther RR; Glassman HN; Jordan DC; Sperzel WD
    Am J Med; 1986 May; 80(5B):73-6. PubMed ID: 2872811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive therapy with once-daily administration of terazosin, a new alpha 1-adrenergic-receptor blocker.
    Abraham PA; Halstenson CE; Matzke GR; Napier JL; Keane WF
    Pharmacotherapy; 1985; 5(5):285-9. PubMed ID: 2866492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.